Form 8K BARINTHUS BIOTHERAPEUTICS PLC For: 13 March
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Barinthus Biotherapeutics PLC (BRNS)
Assess today's live Barinthus Biotherapeutics PLC (BRNS) share price, performance and insights using our live NASDAQ: BRNS stock exchange data.
Analyse the historical data and Barinthus Biotherapeutics PLC share price performance charts on this page. Our technical summary section provides analysis on Barinthus Biotherapeutics share price buy/sell indicators using real-time data (or discuss the Barinthus Biotherapeutics (BRNS) stock price today with other investors in the Barinthus Biotherapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BRNS share price (ISIN: US91864C1071) to enhance your trading decisions with our free investment tools and resources.
What Is the Barinthus Biotherapeutics PLC Share Price Today?
The Barinthus Biotherapeutics share price today is 0.630.
What Is the Stock Symbol for Barinthus Biotherapeutics PLC
The stock symbol (or 'ticker') for Barinthus Biotherapeutics PLC is "BRNS."
What Stock Exchange Does Barinthus Biotherapeutics PLC Trade On?
Barinthus Biotherapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Barinthus Biotherapeutics PLC a Good Stock to Buy?
Determining whether Barinthus Biotherapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Barinthus Biotherapeutics PLC share price performance charts on this page. Our technical summary section provides analysis on Barinthus Biotherapeutics share price buy/sell indicators using real-time data (or discuss the Barinthus Biotherapeutics (BRNS) stock price today with other investors in the Barinthus Biotherapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BRNS share price (ISIN: US91864C1071) to enhance your trading decisions with our free investment tools and resources.
What Is the Barinthus Biotherapeutics PLC Share Price Today?
The Barinthus Biotherapeutics share price today is 0.630.
What Is the Stock Symbol for Barinthus Biotherapeutics PLC
The stock symbol (or 'ticker') for Barinthus Biotherapeutics PLC is "BRNS."
What Stock Exchange Does Barinthus Biotherapeutics PLC Trade On?
Barinthus Biotherapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Barinthus Biotherapeutics PLC a Good Stock to Buy?
Determining whether Barinthus Biotherapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.590
0.639
52 wk Range
0.512
2.920
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5900.639
52 wk Range
0.5122.920
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BRNS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
5.500
Upside
+773.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K BARINTHUS BIOTHERAPEUTICS PLC For: 13 March
- Investing.com
- Vaccitech ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Barinthus Biotherapeutics PLC SWOT Analysis
HBV Breakthrough | BRNS sharpens focus on Hepatitis B Virus treatments, positioning itself to address a significant unmet medical need in a competitive landscape |
Financial Challenges | Negative EPS forecasts and recent workforce reduction highlight BRNS's struggle for profitability, with cash runway extended to Q2 2026 |
Strategic Pivot | Explore BRNS's agile response to market trends, prioritizing HBV and Celiac disease research while streamlining operations |
Market Potential | Analyst price targets range from $3 to $7, reflecting varied outlooks on BRNS's ability to capitalize on its focused pipeline and industry trends |
Compare BRNS to Peers and Sector
Metrics to compare | BRNS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBRNSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.2x | −0.5x | |
PEG Ratio | 0.07 | −0.12 | 0.00 | |
Price/Book | 0.3x | 2.1x | 2.6x | |
Price / LTM Sales | - | 11.7x | 3.2x | |
Upside (Analyst Target) | - | 166.2% | 47.4% | |
Fair Value Upside | Unlock | 23.7% | 6.9% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.500
(+773.02% Upside)
Earnings
Latest Release
13/03/2026
EPS / Forecast
-0.27 / -0.39
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Barinthus Biotherapeutics (NASDAQ: BRNS) Share Price Today?
The Barinthus Biotherapeutics stock price today is 0.630 USD.
What Stock Exchange Does Barinthus Biotherapeutics (BRNS) Trade On?
Barinthus Biotherapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Barinthus Biotherapeutics?
The stock symbol (also called a 'ticker') for Barinthus Biotherapeutics is "BRNS."
What Is the Current Barinthus Biotherapeutics Market Capitalisation?
As of today, Barinthus Biotherapeutics (NASDAQ: BRNS) market cap is 25.730M USD.
What Is Barinthus Biotherapeutics's (BRNS) Earnings Per Share (TTM)?
The Barinthus Biotherapeutics EPS is currently -1.640 (Trailing Twelve Months).
When Is the Next Barinthus Biotherapeutics Earnings Date?
Barinthus Biotherapeutics's next earnings report will be released on 13/05/2026.
Is BRNS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Barinthus Biotherapeutics moving averages and other technical indicators, the daily buy/sell signal for BRNS stock is Strong Buy.
How Many Times Has Barinthus Biotherapeutics Stock Split?
Barinthus Biotherapeutics has split 0 times. (See the BRNS stock split history page for full effective split date and price information.)
How Many Employees Does Barinthus Biotherapeutics Have?
Barinthus Biotherapeutics has 14 employees, based on their latest Companies House report.
What is the current trading status of Barinthus Biotherapeutics (NASDAQ: BRNS)?
As of 28/04/2026, Barinthus Biotherapeutics (BRNS) is trading at a share price of 0.630 USD, with a previous close of 0.630 USD. The stock has fluctuated within a day range of 0.590 USD to 0.639 USD, while its 52-week range spans from 0.512 USD to 2.920 USD.
What Is Barinthus Biotherapeutics (BRNS) Price Target According to Analysts?
The average 12-month price target for Barinthus Biotherapeutics is 5.500 USD, with a high estimate of 7 USD and a low estimate of 4 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +773.02% Upside potential.
What Is the BRNS After Hours Price?
BRNS's last after hours stock price is 0.611 USD, the stock has decreased by -0.019, or -3.020%.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.